GlobeNewsWire
24 Oct 2026, 23:30 UTC · 1h ago
Impact · against what's priced in
Climb Bio sees a modest positive catalyst from Phase 2 initial data showing budoprutug's efficacy in pMN. The establishment of a 2027 timeline for additional data provides a concrete horizon for the next valuation inflection point.
Scored by the NIS engine · methodology.
What the story claims
2 claims · scored −1 bearish … +1 bullish · 2 new · 0 priced in
Low dose (200 mg) budoprutug achieved B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks.
Newpublished 2026-10-24, presents data at ASN Kidney Week 2026
More positive than 93% of claims this week
Additional data from the PrisMN Phase 2 study is anticipated in 2027.
New
Continue reading
5 related stories
Top 3 movers · tap to explore
So whatThis establishes a catalyst horizon for the next major valuation inflection point in FY2027.
More positive than 52% of claims this week
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
4h ago
